Alley Bratzel's questions to Biohaven (BHVN) leadership • Q3 2021
Question
Alley Bratzel, on behalf of Chris Raymond at Piper Sandler, inquired about the composition of the $740 million in potential milestones from the Pfizer deal, specifically the split between regulatory and commercial achievements. She also asked how NURTEC ODT's profile is resonating with physicians compared to a newly approved competitor.
Answer
CEO Dr. Vlad Coric stated that specific details on the milestone split would be available in filings but emphasized the deal's role in accelerating ex-U.S. revenue. He reiterated that NURTEC ODT's unique profile as the only single therapy for both acute treatment and prevention remains a key differentiator and the primary driver of its market share leadership against competitors.